In order to accelerate the integration process of scientific research, technological innovation, and industrial development of the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College System strengthen the system's ability to participate in international innovation and promote the transformation of outstanding achievements.
"Chemical Class 1 Anticoagulant New Drug SAR" project initiating and "New Traditional Chinese Medicine on the Treatment of Vascular Dementia - Parishin" results transferring signing ceremony were held in Beijing under the support of the Ministry of Health, state "Major New Drug Development" science and technology program management office and other related institutions of Beijing,. The vice-president of Chinese Academy of Medical Sciences & Peking Union Medical College Zhan Qimin hosted the meeting. Leaders of the Ministry of Health, office of State New Drug Development, and other related institutions of Beijing attended the meeting.
In recent years, the National Engineering Research Center for the Development of New Drugs has been constantly exploring new ways of combining technology innovation and the market. The research center has been actively expanding cooperation channels with excellent domestic and international R&D and productive facilities, completed nearly a hundred technological transfer projects, developed 26 new drugs so far, and become an important link of our country being active in the intermediate link of drug research and production; furthermore, it has provided important support for industrialization of research findings of domestic high-end research and development institutions represented by the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College.
Under the guidance of Beijing Municipal Science and Technology Commission, and support of related institutions, the National Engineering Research Center for the Development of New Drugs and the famous French multinational enterprise Sanofi signed jointed development agreement of "The 1st Double Targets Anticoagulant Chemical Class1 New Drug SAR Project" on Sep 27ththis year, after nearly two years of communication. With intellectual property licensing, National Engineering Research Center for the Development of New Drugs will be in charge of the industrialization development of this item. The start and implementation of this project marked further enhancement of the power of National Engineering Research Center for the Development of New Drugs using international innovation resources, to undertake international projects, and is also an important step of the center taking major international technology cooperation chances and actively participating in international competition.
"Parishin" is TCM class 5 new drug for the treatment of vascular dementia jointly researched and developed by the National Engineering Research Center for the Development of New Drugs and the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College. This item was greatly supported by the state "Major New Drug Development" science and technology program of the 11th and 12th five-year plan in the process of research and development. Preclinical studies have been completed at present. The successful transfer of the results marked the further improvement of industrial chain from R&D to production of the Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College System. It has become an important symbol of the e-u-r mode of cooperation of joint development, complementary advantages and benefit-sharing, risk-sharing, and also made another outstanding achievement landed in Beijing.